About Akari Therapeutics Plc

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -2.00$ per share.

The book value per share is 1.07$

Akari Therapeutics Plc website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -29M - -25M -2.00 - - 15M 1.07 -27M - -27M